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Alcohol dependence is a chronic disorder that results from
a variety of genetic, psychosocial, and environmental factors.
Relapse prevention for alcohol dependence has traditionally
involved psychosocial and psychotherapeutic interventions.
Pharmacotherapy, however, in conjunction with behavioral
therapy, is generating interest as another modality to prevent
relapse and enhance abstinence. Naltrexone and acamprosate
are at the forefront of the currently available pharmacologi-
cal options. Naltrexone is an opioid receptor antagonist and
is thought to reduce the rewarding effect of alcohol.
Acamprosate normalizes the dysregulation of N-methyl-D-
aspartate (NMDA)-mediated glutamatergic excitation that
occurs in alcohol withdrawal and early abstinence.These
different mechanisms of action and different target neuro-
transmitter systems may endow the two drugs with efficacy
for different aspects of alcohol use behavior. Since not all
patients seem to benefit from naltrexone and acamprosate,
there are ongoing efforts to improve the treatment outcomes
by examining the advantages of combined pharmacotherapy
and exploring the variables that might predict the response
of the medications. In addition, novel medications are being
investigated to assess their efficacy in preventing relapse and
increasing abstinence.
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INTRODUCTION
Alcohol dependence is a chronic disorder that
results from a variety of genetic, psychosocial, and
environment factors.
1 Over the last 20 years, there
has been considerable progress in efforts to reduce
the enormous alcohol related costs to society, such
as traffic accidents in which the driver is intoxi-
cated, and to set boundaries for injudicious
alcohol use in Korea. These socio-cultural changes
have probably been successful in lowering the
prevalence of alcohol abuse but the prevalence of
alcohol dependence seems to have been less af-
fected.
2 In a recent Korean epidemiological study,
3
it was established that 10.20% of the adult popu-
lation has a lifetime prevalence of alcohol depen-
dence (15.97% of men and 4.64% of women)
which makes alcohol dependence the second most
common psychiatric disorder in Korea.
Treating alcohol dependence usually consists of
two phases: detoxification and rehabilitation. The
initial detoxification stage deals with acute with-
drawal symptoms. The later rehabilitation stage
attempts to prevent relapse and develops a life-
style compatible with long-term abstinence.
Whereas detoxification is widely accepted as a
pharmacotherapeutic domain, rehabilitation, in
clinical practice, has traditionally involved psy-
chosocial and psychotherapeutic interventions
consisting of individual and group psycho-
therapy, cognitive-behavioral treatments, and self-
directed groups such as Alcoholics Anonymous.
Although psychosocial treatments have shown
effectiveness in reducing alcohol consumption and
maintaining abstinence, 40 to 70% of patients still
relapse to drinking within a year following treat-
ment.
4 As a part of the efforts to improve the
treatment outcomes for alcohol dependence, phar-
macotherapy is being investigated as another
modality to enhance abstinence and prevent
relapse, complementing psychosocial interven-
tions.
The rationale of using pharmacotherapy for
alcohol dependence is based on several prem-
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ises.
5,6 First, advances in neurobiology have
identified the neurobehavioral effects of alcohol
and their associated neurotransmitter systems
which are related to the development of depen-
dence and, at the same time, are potential targets
for pharmacological approaches. Second, recent
genetic studies have confirmed that alcohol
dependence is a heterogeneous condition. While
some gene variations predispose people to alcohol
dependence, others confer protection. Third, ani-
mal models of alcohol dependence relapse have
demonstrated that pharmacologic agents can
reduce alcohol consumption and have proven to
be fairly predictive of similar responses in human
patients. Fourth, medications have improved the
treatment of other addictive disorders such as
bupropion for nicotine dependence and metha-
done for heroin dependence, encouraging phar-
macotherapies for the treatment of alcohol depen-
dence.
To date, three medications - disulfiram, naltrex-
one, and acamprosate - have been approved by
the U.S. Food and Drug Administration (FDA) for
treatment of alcohol dependence (Table 1). Only
about 20% of eligible patients receive them,
however.
7 Unfortunately, medications are still dis-
paraged as a “crutch” and some still stick to the
old adage, “You can't treat a drug problem with
a drug.”
8
This article discusses (1) the neurobiological
basis of alcohol dependence; (2) the efficacy and
safety of disulfiram, naltrexone and acamprosate,
the approved pharmacotherapies for alcohol de-
pendence; (3) the ongoing issues for improving
the effectiveness of pharmacotherapy, and (4) the
novel pharmacotherapies currently under inves-
tigation.
THE NEUROBIOLOGY OF ALCOHOL DEPEN-
DENCE
For many years, it has been suggested that
alcohol exerts its neurobiological effects mainly by
increasing membrane fluidity, altering the func-
tion of macro-molecules in the cell membrane.
New evidence, however, indicates that alcohol
binds to hydrophobic pockets of proteins, modu-
lating their function by changing their 3-dimen-
sional structure. Proteins that are particularly
sensitive to this effect include ion-channels, neuro-
transmitter receptors, and enzymes involved in
signal transduction.
9 Neurotransmitters with not-
able sensitivity to this effect include dopamine,
serotonin, gamma-aminobutyric-acid (GABA), glu-
tamic acid, adenosine, neuropeptide Y, norep-
inephrine, cannabinoid receptors, and opioid
peptides.
10 These neurotransmitter systems are
involved in the different components of alcohol
dependence and are therefore targets for
pharmacotherapeutic interventions.
The brain reward system: dopamine and endo-
genous opioid
Considerable evidence has emerged suggesting
that the dopamine system plays a central role in
the biology of alcoholism. Mesolimbic dopamine
A10 neurons are activated by alcohol, resulting in
a release of the neurotransmitter in the nucleus
Table 1. Medications for Relapse Prevention of Alcohol Dependence
US-FDA
approved?
Grade of strength
of evidence
Clinical recommendations
Disulfiram Yes B (Fair) Not recommended for routine use in primary care
Naltrexone Yes
A (Good)
FDA-approved options for treatment of alcohol dependence in
conjunction with behavioral therapy Acamprosate Yes
SSRI No
I (Insufficient)
Recommended for patients with comorbid depressive disorders
Ondansetrone No Recommended to reduce drinking frequency and increase
abstinence. Topiramate No
SSRI, Serotonin-Specific Reuptake Inhibitor.Pharmacotherapy of Alcohol Dependence
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accumbens and mediating positive reinforcement
and reward.
11 It is postulated that repeated al-
cohol use sensitizes the system, so that behavioral
stimuli associated with alcohol also cause the
release of dopamine and facilitate additional
alcohol use.
12 This sensitization may account for
the craving and preoccupation with alcohol that
are the hallmarks of alcohol dependence.
The endogenous opioid system seems to play a
modulatory role on the dopaminergic system,
whereby activation of opiate receptors stimulates
the release of dopamine in the brain. Alcohol
consumption increases the release of endorphins
(which are endogenous opioid peptides) in the
brain, thus indirectly activating the dopaminergic
reinforcement/reward system.
13 It has been postu-
lated that individual differences in the sensitivity
of endogenous opioid systems may underlie in-
dividual differences in the intensity of alcohol
craving and the risk of becoming alcohol depen-
dent.
Subclinical withdrawal symptoms: glutamate
and GABA
The facilitation of inhibitory GABAergic and the
inhibition of excitatory glutamatergic neurotrans-
mission are important targets for the acute effects
of alcohol. Potentiation of GABAergic inhibition is
widely accepted as the underlying cause of the
acute sedative effects of alcohol. Long-term adap-
tive changes to the sedative effects of alcohol in
these two neurotransmitter systems are thought to
underlie the development of alcohol dependence.
After chronic exposure to alcohol, there is a com-
pensatory up-regulation of the glutamatergic
system (and down-regulation of the GABA
system) in an attempt to balance alcohol's inhibi-
tory action. The result is an increased tolerance for
alcohol.14 When alcohol is abruptly withdrawn,
however, a state of hyper-excitability emerges.
This is perceived by the patient as a disagreeable
state of arousal, anxiety and sleeplessness and is
the core of the negative affective state which the
alcoholic patient will drink to relieve. These
plastic changes in the brain, brought about by
change in protein synthesis, are only slowly rever-
sible. This may explain the persistence of negative
craving during alcohol withdrawal and why
stable abstinence after acute detoxification is so
difficult to achieve. Antiglutamamatergic agents,
such as NMDA antagonists and anticonvulsant
agents, have been proposed to reduce the moti-
vation for drinking by suppressing symptoms of
alcohol withdrawal. Recent data suggest that
NMDA antagonists may have other beneficial
effects in alcohol dependent patients, such as sub-
stituting for deficits in negative feedback signals
or reducing the development of tolerance/sensi-
tization to alcohol.
15,16
CURRENTLY APPROVED AGENTS FOR
ALCOHOL DEPENDENCE
Aversive agents: disulfiram
The first agent to be approved for treatment of
alcohol dependence was disulfiram. This sub-
stance was serendipitously discovered to be an
agent causing alcohol aversion in Ohio rubber
workers in 1939. The major metabolic pathway for
alcohol metabolism is a two-step enzymatic pro-
cess (ethanol acetaldehyde acetic acid). Disul-
firam is an irreversible inhibitor that blocks the
second stage of alcohol metabolism, causing an
accumulation of toxic intermediate acetaldehyde,
which results in hypotension, flushing, nausea,
and vomiting. The objective of disulfiram treat-
ment is thus to create an aversion to alcohol,
rather than to modulate its neurochemical effects.
Although many studies have been performed with
disufiram, controlled clinical trials demonstrated
inconsistent findings for alcohol drinking out-
comes between disulfiram and placebo, and have
failed to clearly establish the therapeutic benefit of
this treatment in enhancing abstinence.
17 How-
ever, it is difficult to conclude the efficacy of the
treatment through classical double-blind, placebo-
controlled trials, since it is the psychological deter-
rent effect of the drug rather than its biological
effect that is useful.
18 Fuller et al.
19 observed no
significant differences in abstinence rates or in the
time to first relapse among groups taking placebo,
1 mg/day disulfiram (an inactive dose) or 250
mg/day disulfiram (the standard dose). The pa-
tients receiving 250 mg disulfiram, however, had
fewer drinking days once they relapsed than didYoung-Chul Jung and Kee Namkoong
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the other two groups.
The disulfiram dosage is usually 250 mg per
day with a maximum of 500 mg per day. While
normal results of alcohol consumption after taking
disulfiram are palpitations, flushing, nausea,
vomiting and headaches, more severe reactions
could include myocardial infarction, congestive
heart failure, respiratory depression, and death.
The use of disulfiram appears to be most useful
in adherent patients, in special high-risk patients,
and when administration is supervised.
Anticraving agents: naltrexone and acamprosate
Naltrexone and acamprosate are at the fore-
front of currently available pharmacological
options and they share many important features
20
(Table 2). Most of the concerns in using
medications for relapse prevention are probably
related to the possible intrinsic dependence
potential. However, there is no evidence that
naltrexone or acamprosate have developed either
tolerance or withdrawal symptoms, including
rebound drinking when treatment is ceased, and
nor do they have any overt psychoactive effects
on the central nervous system. In addition, both
drugs do not have pharmacological or phar-
macokinetic interaction with alcohol and so the
serious side effects associated with disulfiram are
not troublesome when using naltrexone or
acamprosate.
The important difference between naltrexone
and acamprosate are mainly attributed to their
mechanisms of action. Naltrexone is an anta-
gonist at the opioid receptors, which are known
to mediate the rewarding effects of alcohol, and
is thus thought to reduce the desire or craving
for rewarding. Although less well defined, acam-
prosate normalizes the dysregulation of NMDA-
mediated glutamatergic excitation that occurs in
alcohol withdrawal and early abstinence. This
effect probably attenuates the desire or craving
for reduce of tension. These different mecha-
nisms of actions may endow the two drugs with
efficacy for different components of drinking.
Opioid antagonist: naltrexone
The USA FDA's approval of naltrexone for the
treatment of alcohol dependence was based
mainly on two small, double-blind, placebo-con-
trolled trials demonstrating a reduced rate of
Table 2. Comparison of the Characteristics of Naltrexone and Acamprosate
Naltrexone Acamprosate
Efficacy parameters
Increased abstinence Maybe Yes
Decreased heavy drinking Yes Maybe
Longer-term efficacy No Yes
Sustained efficacy post-treatment No Yes
Onset of action Rapid Slow
Compliance Variable Good
Contingent on psychosocial intervention Variable Independent
Safety parameters
Interaction with alcohol No No
Intrinsic dependence potential No No
Overall safety profile Good Good
Hepatic impact Yes No
Clinically relevant drug interactions Yes NoPharmacotherapy of Alcohol Dependence
Yonsei Med J Vol. 47, No. 2, 2006
relapse to heavy drinking, reduced craving, and
less frequent drinking in naltrexone-treated
patients.
22,23 During the following years, several
more trials have followed and three meta-analyses
have concluded that naltrexone is efficacious in
the treatment of alcohol dependence.
24-26 The most
consistent finding obtained with naltrexone is an
increased time to first relapse (typically defined as
more than 5 drinks/day in males, 4 drinks/day in
females). The decrease in relapse rate, however,
has not been observed in all studies. Such dif-
ferences in results are seen even in the largest
trial.
27 Several factors may explain the discrep-
ancies in results of the different clinical trials of
naltrexone. The animal models of relapse indicate
that naltrexone blocks cue-induced relapse but is
less effective against stress-induced relapse.
28 The
effect of naltrexone on relapse may, to some
extent, be dependent on associated psycho-
therapy, since naltrexone was found to be more
effective in patients receiving training in coping
skills than in those receiving supportive therapy
alone.
29 Compliance may be a limiting factor in
naltrexone treatment.
30-32 Monti et al.
32 demon-
strated a significant treatment outcome only when
non-compliant subjects were excluded from the
analysis. A large multi-site, double blind, placebo-
controlled trial with an injectable, sustained-re-
lease formation, (a strategy to improve compli-
ance) demonstrated that relapse to heavy drinking
decreased in patients receiving depot preparation
compared to placebo.
33
A conceptual framework for integrating the
clinical data on naltrexone has been proposed by
Sinclair,
34 who suggested that naltrexone is useful
for preventing relapse rather than at maintaining
absolute abstinence. Thus, the contingency of
drinking alcohol and taking naltrexone is impor-
tant in bringing to light treatment effects. In a
recent systematic meta-analysis of 24 placebo-con-
trolled trials, including a total of 2861 patients,
short-term naltrexone therapy significantly de-
creased relapse rate (relative risk 0.64), but did not
enhance absolute abstinence (relative risk 0.91).
35
For the first 90 days of abstinence, when the
risk of relapse is greatest, the recommended
dosage of naltrexone is a single dose of 50 mg per
day but doses of 25 mg to 100 mg daily are some-
times used. The most common side effects are
nausea (10%), headache (7%), anxiety (2%) and
sedation (2%).
36 Naltrexone has been shown to
have dose-related hepatotoxicity, although gen-
erally this occurs at doses of 300 mg per day,
higher than those recommended for treatment of
alcohol dependence. The drug is contraindicated
in patients with hepatitis or liver failure, and a
monthly check of hepatic transaminase levels is
recommended, for the first three months and
every three months thereafter.
NMDA/ GABA receptor modulator: Acamprosate
Acamprosate was investigated in nearly 20 con-
trolled, published trials with about 4000 patients
and these studies have produced consistent results
showing that acamprosate treatment is superior to
placebos in maintaining abstinence.
37 In all but
three clinically controlled published studies, the
proportion of acamprosate-treated patients ab-
staining at the end of the study was twice as high
as patients receiving placebos. In addition, two
studies
38,39 evaluated long-term abstinence for 1-
ear after the end of the treatment period, and both
showed that treatment effects were maintained. A
systematic metaanalysis
37 in which clinical data
from 17 trials were reanalyzed concluded that the
treatment effect could increase with time.
Since most of the trials were undertaken in
Europe, it was considered important to evaluate
the efficacy and safety of acamprosate in different
ethnic groups, given the emerging role of genetic
and cultural issues in drug treatment. In a study
by Namkoong et al.,
40 however, acamprosate did
not show any treatment benefits when compared
to the placebo. This negative finding might be ex-
plained by the sample characteristics (i.e., a more
severe form of alcohol dependence, a lower level
of social support, a short interval between the last
drink and the first medication), the dosage issues
of acamprosate, the short study period (8 weeks),
and the variable concomitant psychosocial treat-
ment.
Acamprosate is available in 333-mg enteric
coated tablets. Dosing is determined by weight (
60 kg: 1998 mg, < 60 kg: 1332 mg). It is not meta-
bolized but is eliminated by renal excretion, and
should therefore be given cautiously with renal
impairment. Acamprosate is well tolerated withYoung-Chul Jung and Kee Namkoong
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limited side effects, most commonly transient
diarrhea (10%) and headache (20%). Like naltrex-
one and disulfiram, acamprosate is FDA pregn-
ancy category C, i.e., there have been adverse
effects on the fetus in animal studies but no
human trials have been performed.
IMPROVING THE EFFECTIVENESS OF
PHARMACOTHERPY
Combination Pharmacotherapy: Naltrexone plus
Acamprosate
Combining naltrexone and acamprosate in the
treatment of alcohol dependence is an attractive
concept for several reasons. Since naltrexone and
acamprosate have different mechanisms of action
and different target neurotransmitter systems, pre-
sumably, they affect different aspects of alcohol
use behavior. (Naltrexone decreases alcohol con-
sumption and acamprosate stabilizes abstinence.)
Pharmacokinetic and behavioral assessments of
combining naltrexone and acamprosate have
found the combination to be safe.
Kiefer et al.
41 performed a randomized, double-
blind, placebo-controlled, clinical trial of 160 al-
cohol-dependent patients and assessed the effi-
cacy of naltrexone and acamprosate, as mono-
therapy and in combination. It was demonstrated
that the proportion of patients remaining abso-
lutely abstinent at the end of the 12-week treat-
ment period was around twice as high in the
combination therapy group than in the mono-
therapy group (placebo 25%, naltrexone alone
65%, acamprosate alone 50%, combination therapy
73%). Even though further relapse occurred
during the follow-up period, the relative treat-
ment benefits between the three treatment groups
and the placebo group was maintained at the end
of the 3-month open label phase. There was,
however, no significant difference between the
three treatment groups (placebo 20%, naltrexone
alone 47%, acamprosate alone 46%, combination
therapy 66%).
42 Although combination therapy
was generally well tolerated, the incidence of diar-
rhea (13.8%) and nausea (5.6%) was significantly
greater than in the monotherapy groups, perhaps
due to a pharmacokinetic interaction.
There are several possible explanations for the
superior efficacy of the combination treatment.
43
First, there may be subgroups that respond selec-
tively to naltrexone or acamprosate and thus the
added benefit of combination therapy would be
merely explained by the recruitment of additional
responder patients. A hypothesis of such patient
subgroups may be that 'reward' craving drinkers
would respond better to naltrexone and 'relief'
craving drinkers would respond better to acam-
prosate (Fig. 1). Attempts to find variables that
might predict the response of medications will be
discussed later. Second, the combination produces
a synergic anticraving effect as the two drugs
interfere with distinct biological aspects of the
craving process. Third, pharmacokinetic interac-
tion might underlie the observed treatment
benefits, whereby bioavailability might be en-
hanced by co-administration of the other drug.
The ongoing COMBINE study
44 plans to recruit
1,375 subjects at 11 sites to examine treatment
interactions between naltrexone, acamprosate and
two behavioral interventions (medical manage-
ment and combined behavioral interventions). The
data from COMBINE will answer important ques-
tions regarding the effectiveness of naltrexone and
acamprosate both alone and in combination, as
well as that of psychosocial treatment.
Fig. 1. A representation of the neuroadaptive model of
craving and possible mechanisms of naltrexone and
acamprosate.Pharmacotherapy of Alcohol Dependence
Yonsei Med J Vol. 47, No. 2, 2006
The matching hypothesis: the three pathway
model of craving
Since not all patients seem to benefit from the
different anticraving drugs, the use of matching
procedures might be important in improving the
effectiveness of treatment with anticraving com-
pounds.
45 The type of craving could possibly be
an important predictor or matching variable with
anticraving compounds. In general, craving
mainly refers to the strong desire or urge to ex-
perience the effect of a previously experienced
psychoactive substance.
46 Despite the simplicity of
this definition, a wide variety of craving concepts
are used in the research and clinical field. Verheul
et al.
47 have proposed a novel three pathway
model of craving in alcoholics. This model sug-
gests that craving is likely to result from distinct
psychobiological mechanisms and that the efficacy
of different anti-craving compounds is associated
with individual differences in craving: (1) The
reward pathway suggests that craving or desire
for the rewarding, stimulating and/or enhancing
effects of alcohol might result from either dopami-
nergic/opioidergic dysregulation or a personality
style characterized by reward seeking and/or
hedonism. (2) The relief pathway suggests that
craving or desire for the reduction of tension,
arousal or withdrawal might result from either
GABAergic/glutamatergic dysregulation or a per-
sonality style characterized by stress reactivity,
anxiety sensitivity, and/or hyperarousability. (3)
The obsessive pathway can be defined as a lack
of control over intrusive thoughts about drinking
resulting in impaired functioning. This pathway
of craving might result from serotonin deficiency
or a personality style characterized by low con-
straint or disinhibition.
Some studies found that patients with high
levels of alcohol craving are most likely to benefit
from naltrexone treatment.
48,49 No distinction,
however, was made between reward, relief and
obsessive craving. Palfai et al.
50 conducted a study
among hazardous drinkers and suggested that
naltrexone may be particularly effective in re-
ducing the cue-elicited positive reinforcement of
alcohol for those with high positive alcohol out-
come expectancies. Positive outcome expectancies
also moderated the effects of naltrexone on sub-
jective reports of stimulation following drinking.
Lesch et al.
51 conducted a long-term, prospec-
tive study to assess the efficacy of acamprosate
based on the four subtypes of alcohol dependent-
patients. Consistent with their matching hypo-
thesis, based on the three pathway model of
Verheul et al.,
48 acamprosate differentially re-
duced alcohol intake in those patients who use
alcohol to counteract withdrawal symptoms (Type
I), and in patients who use alcohol as a conflict-
solving and anxiety reducing agent (Type II), but
not in patients who ingest alcohol to self-medicate
affective disorders (Type III) or patients with a
history of cerebral impairment that precedes the
development of alcohol dependence (Type IV). A
recent study including the pooled data of 1,485
alcohol-dependent patients from seven rando-
mized, controlled trials comparing acamprosate
and a placebo, directly tested the matching hypo-
thesis that acamprosate would be more effective
in patients with high physical dependence at
baseline, negative family history of alcoholism,
late age of onset, serious anxiety symptomatology
at baseline, severe craving at baseline, and female
gender.
52 In contrast to the expectations, the authors
found that none of these theoretically relevant
clinical matching variables predicted the treatment
effectiveness of acamprosate. Similarly, another
pooled analysis of 11 trials by Sass et al.
53 did not
find any demographical, psychopathological or
biological predictors for acamprosate efficacy.
It should be noted that the three-pathway
model by Verheul et al.
48 and related matching
hypotheses might not cover all the possible mech-
anisms of action of anti-craving medications. For
example, a recent study showed that naltrexone
not only includes an opioid-receptor blockade, but
that it indirectly increased hypothalamic pituitary
adrenocortical (HPA) activity, resulting in higher
adrenocorticotropic hormone (ACTH) and cortisol
levels, which may in turn be partially responsible
for the effect of naltrexone on drinking and
craving.
54
Pharmacogenomics: -Opioid Receptor Poly μ mor-
phism
Investigating the role of genetics in predicting
treatment outcomes is one promising area ofYoung-Chul Jung and Kee Namkoong
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research since a genetic basis of for alcoholism
(heritability rate, 50-60%) is well established.
55
Monterossso et al.
49 explored the predictors of
naltrexone response in a double-blind, placebo-
controlled trial and demonstrated significant in-
teractions between treatment condition and family
history of alcohol problems. Some studies have
investigated individual differences with respect to
sensitivity in the hypothalamic pituitary adrenal
axis to naltrexone administration. King et al.
56
examined the neuroendocrine and mood re-
sponses to oral naltrexone as a function of the
biological family history of alcoholism. The results
demonstrated the potential biological bases of
altered opioidergic sensitivity in those persons
with an assumed greater inherited vulnerability
for future alcoholism. Meanwhile, studies of
family history as a predictor of treatment response
have led to speculation that naltrexone may func-
tion differently in genetically predisposed indi-
viduals.
Naltrexone has a high affinity for the -opioid μ
receptor, which is hypothesized to be the principal
site of action of the drug. It has been hypothesized
that sequence variation in the gene encoding the
-receptor may result in a receptor with altered μ
expression, structure, or function, and as a conse-
quence, may increase or decrease an individual's
susceptibility to substance dependence.
57 Oslin et
al.
58 examined the association between two
specific polymorphisms of the gene encoding the
-opioid receptor and treatment outcomes, mea μ -
sured over 12 weeks, in alcohol dependent
patients who were prescribed naltrexone or a
placebo. Patients with one or two copies of the
Asp40 allele treated with naltrexone had signifi-
cantly lower rates of relapse (26.1% versus 47.9%;
p = 0.0044) and took a longer time to return to
heavy drinking than those homozygous for the
Asn40 allele. There were no differences in relapse
rates or abstinence rates between the two geno-
type groups among those assigned to placebo.
Meanwhile, Kim et al.
59 reported that the allele
frequency of the Asp40 allele was 39.7% in the
Korean alcohol dependent group, which is con-
sistent with previous studies demonstrating a
higher Asp40 allele frequency in the Asian popu-
lation. Within the alcohol dependent group, the
Asp40 allele was associated with more drinking
days. The finding of a genotype that predicts
success with naltrexone, if replicated, will provide
a pharmacogenetic tool to enhance the matching
of patients to treatment and encourage the search
for additional functional polymorphisms.
THE DEVELOPMENT OF NOVEL DRUGS
FOR ALCOHOL DEPENDENCE
Serotonergic agents and Ondansetron (5-HT3 an-
tagonist)
During the last two decades, a number of drugs
acting on serotonergic neurotransmission have
been studied in alcohol dependence, since sero-
tonin is widely implicated in a variety of consum-
matory behaviors and impulsivity. These agents
are either selective serotonin reuptake inhibitors
or receptor agonist/antagonists. Most of this
work, however, has used small samples with rela-
tively short treatment periods. Selective serotonin
reuptake inhibitors, despite their effectiveness in
animals, have shown inconsistent or disappoin-
ting results in humans
60-65 and so the usefulness
is still controversial.
17 Meanwhile, no evidence of
clinical efficacy in alcohol-dependent has been
obtained with ritanserin (5-HT2 anatagonist).
66,67 In
addition, a meta-analysis of studies performed
with bupropion (5-HT1 partial agonist) concluded
that any efficacy of bupropion was secondary to
an anxiolytic effect, rather than on drinking
perse.
68
Of the numerous serotonergic drugs which
have been suggested as pharmacotherapies for
alcohol dependence treatment, ondansetron, a
5-HT3 antagonist that is FDA-approved as an
antiemetic, appears to be the most promising.
69
The 5-HT3 receptor is involved in the expression
of alcohol's rewarding effects. Behavioral phar-
macological studies show that many of the reward
effects of alcohol are mediated by interactions
between DA and the 5-HT3 receptor in the mid-
brain and cortex.
70,71 5-HT3 receptors are densely
distributed in the terminals of mesocorticolimbic
DA-containing neurons where they regulate DA
release in these brain regions. Following a pre-
vious clinical trial,
72 Johnson et al.
73 evaluated
ondansetron as a treatment for alcohol depen-Pharmacotherapy of Alcohol Dependence
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dence in a 12-week, double-blind, placebo-con-
trolled trial of 321 patients. The early-onset, al-
cohol dependent group treated with ondansetron
(particularly 4 g/kg b.i.d.) reported fewer drinks μ
per day and fewer drinks per drinking days,
while the late-onset group treated with ondan-
setron did not differ from those treated with
placebo. It is interesting that while serotonine
reuptake inhibitors have little effect on drinking
among early-onset alcoholics, ondansetron, with
functionally opposite effects in the serotonergic
system, is effective for the early-onset subtype.
Sufficient evidence exists that early-onset alcoholics
are more prone to serotonergic dysfunction than
late-onset alcoholics.
74,75
Mood stabilizers/ Anticonvulsants and Topira-
mate (GABA agonist)
Mood stabilizers and anticonvulsants decrease
alcohol consumption in experimental animals.
Clinical trials, however, have not provided clear
evidence of the efficacy of treatment for alcohol
dependence. The controlled trials of lithium did
not demonstrate efficacy in either non-depressed
or depressed alcohol-dependent patients and
Garbutt et al.
17 concluded that lithium lacks effi-
cacy in the treatment of primary alcohol depen-
dence. More promising are results with non-
benzodiazepine anticonvulsants such as carba-
mazepinem, valproate, gabapentin, vigabatrin and
topiramate.
76
Topiramate, although only approved by the
FDA for seizure disorders, was evaluated in the
treatment of alcohol dependence because of its
effects on GABAergic and glutamatergic systems.
It has been shown to augment GABA function
and inhibit specific glutamatergic pathways at the
AMPA/kinate receptors. This may decrease the
cortical expression of alcohol reward by de-
creasing the midbrain dopamine function.
77 In a
12-week double-blind, placebo-controlled trial of
150 alcohol dependent patients, topiramate was
more effective than placebo in initiating absti-
nence and in reducing self-reported drinks per
day, drinks per drinking days, and heavy
drinking days. Compared with a placebo, it also
significantly reduced craving as assessed with
Obsessive Compulsive Drinking Scale. Topiramate
was equally effective in both early-onset and
late-onset alcohol dependence.
78 The study used
an escalating dose of 25 to 300 mg per day. Hyper-
sensitivity to the drug was the only known contra-
indication. No serious adverse events occurred.
Paresthesia was the most common adverse effect,
which includes dizziness, somnolence, diplopia
and nausea.
CONCLUSION
Important advances have been made in the
development of pharmacotherapy in alcohol
dependence and it is experiencing a major shift
in direction. There is clear evidence of the effi-
cacy and safety of natrexone and acamprosate,
and still more novel medications are under
investigation. In addition, important questions
remain regarding the optimal dose and duration
of treatment, the role of combinations of medi-
cations, and the treatment subtypes of alcohol
dependent patients.
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